TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31600833

Group type: EXPERIMENTAL
Intervention: bFGF related decapeptide solution plus Tacrolimus 0.1% ointment (M + T)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Tacrolimus 0.1% ointment (T)
Number of subjects: 94
Study: 28274323

Group type: EXPERIMENTAL
Intervention: Group education sessions about menopause (2 sessions)
Number of subjects: 131

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 131
Study: 24914429

Group type: EXPERIMENTAL
Intervention: School-based oral health intervention programme with dental hygienists working 4 hours weekly for two years, including fluoride varnish treatments every 6 months.
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control group with no intervention.
Number of subjects: 534
Study: 24160382

Group type: EXPERIMENTAL
Intervention: Intracameral triamcinolone acetonide 0.5 mg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Intracameral triamcinolone acetonide 1.0 mg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Intracameral triamcinolone acetonide 2.0 mg
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (no triamcinolone acetonide)
Number of subjects: 126
Study: 21792066

Group type: EXPERIMENTAL
Intervention: Full mitochondrial DNA (mtDNA) sequence analysis
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: African mtDNA haplogroup
Number of subjects: 423
Study: 18728037

Group type: EXPERIMENTAL
Intervention: Phosphorylcholine coating (PC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-coated circuits
Number of subjects: 120
Study: 17699190

Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 1676

Group type: COMPARATOR
Intervention: Usual-protein diet
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Very low-protein diet with dietary supplements (study B)
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Low-protein diet (study A)
Number of subjects: 1676
Study: 15729207

Group type: EXPERIMENTAL
Intervention: Optimal cytoreductive surgery by well trained specialists
Number of subjects: 190000

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 190000
Study: 11369159

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (median first dose 75 microg/h, median final dose 100 microg/h)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (for > or =3 months until death)
Number of subjects: 73
Study: 9164988

Group type: EXPERIMENTAL
Intervention: 50 mg zinc gluconate/d for 15 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8333158

Group type: EXPERIMENTAL
Intervention: Test stimulus at 10 c/deg with a 10 c/deg masker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test stimuli at 2 c/deg and 8 c/deg with the same masker
Number of subjects: 0
Study: 3653532

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg twice daily for 1 week
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29429464

Group type: EXPERIMENTAL
Intervention: L-DRD4 genotype
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: DRD4 exon III 48bp VNTR
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Mother's rejection/denial
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Interaction between sex and DRD4 exon III 48bp VNTR
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Interaction between DRD4 exon III 48bp VNTR and mother's rejection/denial
Number of subjects: 164
Study: 27712733

Group type: EXPERIMENTAL
Intervention: Prophylactic ipsilateral ulnar compression during radial artery hemostasis
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Standard patent hemostasis protocol
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Prophylactic ipsilateral ulnar compression
Number of subjects: 3000
Study: 24744272

Group type: EXPERIMENTAL
Intervention: Continuous warfarin therapy (group 2)
Number of subjects: 1584

Group type: COMPARATOR
Intervention: Warfarin discontinuation (group 1)
Number of subjects: 1584
Study: 24473583

Group type: EXPERIMENTAL
Intervention: Dense cranial electroacupuncture stimulation (DCEAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study: 21209504

Group type: EXPERIMENTAL
Intervention: Training of school teachers, training of journalists, interactive discussions with school children, communication through local media
Number of subjects: 288
Study: 18536787

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with carboplatin and paclitaxel (CbP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard platinum-based doublet (without bevacizumab)
Number of subjects: 0
Study: 16202177

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/d for 6 weeks then 10 mg/d for 6 weeks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Donepezil for patients with clinically significant depressive symptoms
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 12647275

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10772527

Group type: EXPERIMENTAL
Intervention: Didanosine 50 mg/m2 orally every 12 hr
Number of subjects: 77
Study: 8868268

Group type: EXPERIMENTAL
Intervention: High resistance (HR group: 4 sets, 8 reps, 8RM loading)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low resistance (LR group: 4 sets, 24 reps, 24RM loading)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Loaded kicking movements (LK group: 4 sets, 16 reps, 16RM loading)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CO group)
Number of subjects: 22
Study: 1299489

Group type: EXPERIMENTAL
Intervention: Vitamin/mineral supplementation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 6438048

Group type: EXPERIMENTAL
Intervention: 600 mg enoxacin as a single oral dose
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 400 mg enoxacin given twice with an interval of 4 hours
Number of subjects: 22
Study: 31806612

Group type: EXPERIMENTAL
Intervention: Congruent eye and hand movement training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard visual scanning therapy (VST)
Number of subjects: 30
Study: 28390970

Group type: EXPERIMENTAL
Intervention: 1.5mA anodal tDCS over left dorsolateral prefrontal cortex
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 29736463

Group type: EXPERIMENTAL
Intervention: Supervised functional electrical stimulation (FES) cycling
Number of subjects: 16

Group type: COMPARATOR
Intervention: Passive cycling (Control)
Number of subjects: 16
Study: 24866478

Group type: EXPERIMENTAL
Intervention: OC000459 25 mg once daily
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: OC000459 pooled dose groups
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: OC000459 in atopic eosinophilic subjects
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: OC000459 in subjects aged ≤40 years
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: OC000459
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 22881465

Group type: EXPERIMENTAL
Intervention: Low fluence multiple pass diode laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: High fluence single pass IPL
Number of subjects: 30
Study: 18488223

Group type: EXPERIMENTAL
Intervention: Newcastle disease virus (NDV) infected autologous tumour cell vaccine (ATV‐NDV), administered in six doses after liver resection.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 50
Study: 17244231

Group type: EXPERIMENTAL
Intervention: Full coverage hard maxillary stabilization splints
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintaining or increasing contact with the splint
Number of subjects: 0
Study: 16255987

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Ap‐237
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Intramuscular morphine
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Stilamin (250 microg/h)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Stilamin (500 microg/h)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Sandostatin
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Pentaerythritol tetranitrate (PTN)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Associated application of ISDN and GTN
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Associated application with PTN
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Anisodamine or atropine
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Buscopan
Number of subjects: 157
Study: 11851659

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy using dye‐guided or gamma probe‐guided method, combined with step sectioning, haematoxylin and eosin staining, and immunohistochemistry.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine axillary lymph node dissection (ALND)
Number of subjects: 0
Study: 10461843

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine vaginal douching
Number of subjects: 1130

Group type: COMPARATOR
Intervention: Sterile saline vaginal douching
Number of subjects: 1130
Study: 7588340

Group type: EXPERIMENTAL
Intervention: Scotchbond 2 Light Cure Dental Adhesive
Number of subjects: 32

Group type: COMPARATOR
Intervention: Tubulitec Primer and Liner
Number of subjects: 32
Study: 1979900

Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride 1.5 mg/day for the first week and 3.0 mg/day for two weeks (Group E)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Bethanechol chloride 15 mg three times daily for three weeks (Group B)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride (Group E)
Number of subjects: 323
Study: 457886

Group type: EXPERIMENTAL
Intervention: Ego-involvement condition (manipulated through instructions, data identification method, and E interaction with a confederate)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Task-involvement condition (manipulated through instructions, data identification method, and E interaction with a confederate)
Number of subjects: 48
Study: 31592824

Group type: EXPERIMENTAL
Intervention: Nanosecond pulsed electric field (nsPEF) treatment
Number of subjects: 72
Study: 31558473

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Elevated baseline VEGFA
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Elevated baseline thyroglobulin
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Combined VEGFA/thyroglobulin signatures
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: BRAF mutations
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: RAS mutations
Number of subjects: 417
Study: 28385353

Group type: EXPERIMENTAL
Intervention: Fixed triple therapy (extrafine beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide)
Number of subjects: 2691

Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 2691

Group type: EXPERIMENTAL
Intervention: Open triple therapy (BDP/FF plus tiotropium)
Number of subjects: 2691

Group type: EXPERIMENTAL
Intervention: Fixed triple therapy
Number of subjects: 2691

Group type: EXPERIMENTAL
Intervention: Open triple therapy
Number of subjects: 2691
Study: 25972054

Group type: EXPERIMENTAL
Intervention: TEE-guided early direct current cardioversion (DCC)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional treatment with dabigatran-etexilat for 3 weeks followed by DCC
Number of subjects: 126
Study: 24229084

Group type: EXPERIMENTAL
Intervention: ALA-rich linseed oil mixture (17 g/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Olive oil (17 g/d)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cheek cell FA
Number of subjects: 38
Study: 21253725

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of tranexamic acid (TXA) 2000 mg/20 ml
Number of subjects: 100

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 100
Study: 19101222

Group type: EXPERIMENTAL
Intervention: Taxus stent
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 2736
Study: 17192509

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 8
Study: 14709369

Group type: EXPERIMENTAL
Intervention: Postprandial remnant-like particle (RLP) metabolism in the IR group
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Postprandial RLP-C concentration changes during the fat-loading test in the IR group
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Correlation of HOMA-R with fasting and postprandial triglyceride and RLP-C
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Postprandial RLP-C concentration as a predictor of HOMA-R
Number of subjects: 52
Study: 11468543

Group type: COMPARATOR
Intervention: Nifedipine (30 mg once daily)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Lisinopril (10 mg once daily)
Number of subjects: 154
Study: 9721802

Group type: EXPERIMENTAL
Intervention: High-dose azathioprine (5 mg/kg/day, adjusted to maintain 6-TGN levels between 100 and 200 pmol/8 x 10(8) RBCs)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Low-dose azathioprine (3 mg/kg on day 0, then 2 mg/kg/day the first week and 1 mg/kg/day thereafter)
Number of subjects: 360
Study: 7988502

Group type: EXPERIMENTAL
Intervention: Bromides (BR) as add‐on therapy
Number of subjects: 22
Study: 2574054

Group type: EXPERIMENTAL
Intervention: 4 mg acrivastine
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 789445

Group type: EXPERIMENTAL
Intervention: Intravenous Ritodrine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31348498

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Voice break timing
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Testosterone levels at voice break
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: LH levels at voice break
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Bi-testicular volume at voice break
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Correlation with other milestones
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Age-specific BMI association
Number of subjects: 730
Study: 28935921

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus casei strain Shirota‐fermented milk)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 70
Study: 25902552

Group type: EXPERIMENTAL
Intervention: High CHO diet (70% CHO)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low CHO diet (25% CHO)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal CHO diet (56% CHO)
Number of subjects: 19
Study: 22459017

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alert state
Number of subjects: 0
Study: 20870365

Group type: EXPERIMENTAL
Intervention: Abstinence-contingent condition (CM)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 154
Study: 19849864

Group type: EXPERIMENTAL
Intervention: Coroflex Please stent
Number of subjects: 900

Group type: COMPARATOR
Intervention: Taxus Liberte stent
Number of subjects: 900
Study: 16421011

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Triple antiplatelet therapy
Number of subjects: 22
Study: 12927950

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg/day
Number of subjects: 0
Study: 10852750

Group type: COMPARATOR
Intervention: 100% O(2) at resting minute ventilation (V E) for 60 min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: O(2) containing 4.5 to 4.8% CO(2) at 2 to 6 times resting V E for 90 min
Number of subjects: 7
Study: 9089471

Group type: EXPERIMENTAL
Intervention: GHRH (4 bolus injections of 50 micrograms GHRH)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1584260

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiation therapy (fluorouracil 1000 mg/m² daily for 4 days and cisplatin 75 mg/m² on the first day plus 5000 cGy of radiation)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Radiation therapy alone (6400 cGy)
Number of subjects: 121
Study: 2865677

Group type: EXPERIMENTAL
Intervention: Patients not receiving beta-adrenergic blocking agents
Number of subjects: 2999

Group type: COMPARATOR
Intervention: Patients receiving beta-adrenergic blocking agents
Number of subjects: 2999
Study: 30784332

Group type: EXPERIMENTAL
Intervention: Intraoperative ventilation with pure oxygen (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional air/oxygen 1:1 mixture (Group A)
Number of subjects: 100
Study: 29747966

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 28166067

Group type: EXPERIMENTAL
Intervention: Ultrasound guided femoral nerve block with 20 ml of 2% lignocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous fentanyl 2 mc/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasound guided femoral nerve block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 40
Study: 23826633

Group type: EXPERIMENTAL
Intervention: EG2 (four PE sessions/week of high intensity)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: EG1 (four PE sessions/week)
Number of subjects: 67

Group type: COMPARATOR
Intervention: CG (usual PE, two sessions/week)
Number of subjects: 67
Study: 21830317

Group type: EXPERIMENTAL
Intervention: Initial antibiotic therapy to eradicate Pseudomonas aeruginosa (Pa) followed by 15 months of intermittent maintenance antibiotics.
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Successful initial eradication of Pseudomonas aeruginosa (Pa).
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Persistent Pseudomonas aeruginosa (Pa) during the maintenance phase after failure to initially eradicate.
Number of subjects: 282
Study: 20110697

Group type: EXPERIMENTAL
Intervention: MFP dentifrice (1,450 microg F/g)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Non-F dentifrice
Number of subjects: 1
Study: 18320252

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1.8 g/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no EPA)
Number of subjects: 12
Study: 11176000

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials in neurosurgery
Number of subjects: 0
Study: 10470456

Group type: EXPERIMENTAL
Intervention: Anatomic staging of cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine use of staging in a population
Number of subjects: 0
Study: 7998893

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% cream
Number of subjects: 125

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 125
Study: 3135392

Group type: EXPERIMENTAL
Intervention: Recombinant interferon gamma (IFN gamma)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31872328

Group type: EXPERIMENTAL
Intervention: Vergence eye movement task (eight movements)
Number of subjects: 27
Study: 28093999

Group type: EXPERIMENTAL
Intervention: 1000 U of C1-INH with 24,000 U of rHuPH20
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 2000 U of C1-INH with 48,000 U of rHuPH20
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Study completers
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nonprophylaxis users at baseline on high treatment doses
Number of subjects: 41
Study: 25993547

Group type: EXPERIMENTAL
Intervention: ALO-02
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 23891455

Group type: EXPERIMENTAL
Intervention: Hand hygiene before donning nonsterile gloves
Number of subjects: 100

Group type: COMPARATOR
Intervention: Directly don nonsterile gloves
Number of subjects: 100
Study: 21794822

Group type: EXPERIMENTAL
Intervention: Physiotherapy manual techniques, 1-2 sessions per week for six months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (GC)
Number of subjects: 29
Study: 19262230

Group type: EXPERIMENTAL
Intervention: Candesartan 8‐16 mg/day (n = 91)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Enalapril 10‐20 mg/day (n = 105)
Number of subjects: 196
Study: 16353140

Group type: EXPERIMENTAL
Intervention: Pemirolast (10 mg) administered orally 2 hours before paclitaxel infusion.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (oral lactose) administered 2 hours before paclitaxel infusion.
Number of subjects: 84
Study: 15342830

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A (BoNT) injections in the submandibular glands
Number of subjects: 45

Group type: COMPARATOR
Intervention: Scopolamine treatment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Baseline measurements
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Follow-up assessments after BoNT injections
Number of subjects: 45
Study: 10932998

Group type: EXPERIMENTAL
Intervention: New pain management standard
Number of subjects: 173
Study: 9065194

Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg followed by Misoprostol 400 micrograms after 48 hours
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Surgical abortion
Number of subjects: 1373
Study: 8421173

Group type: EXPERIMENTAL
Intervention: Mycobacterium w vaccine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56